Logo

Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS I and II Studies for Multiple Sclerosis

Share this

Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS I and II Studies for Multiple Sclerosis

Shots:

  • The P-III ASCLEPIOS I and II (NCT02792218 and NCT02792231) studies involve assessing of Ofatumumab (20mg- SC- monthly) vs Aubagio (teriflunomide- 14mg- qd) in 1-882 patients with MS aged 18-55yrs. across 37 countries
  • The P-III ASCLEPIOS I and II studies resulted in meetings their 1EPs & 2EPs i.e- @30mos. reduction in annualized relapse rate evaluated by ARR & delayed time to disability progression- @6mos. confirmed disability improvement respectively- additional 2EPs will be presented at ECTRIMS
  • Ofatumumab is mAb targeting CD20 molecule on the B-cell surface and inducing potent B-cell lysis and depletion with its expected initiation of regulatory submission in H2’19. In Dec’2015- Genmab granted rights for ofatumumab in all indications including MS to Novartis

Click here to­ read full press release/ article | Ref: Novartis | Image: WSJ


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions